• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Prevalence of clopidogrel resistance in patients with atrial fibrillation undergoing percutaneous coronary intervention.接受经皮冠状动脉介入治疗的心房颤动患者中氯吡格雷抵抗的患病率。
Postepy Kardiol Interwencyjnej. 2025 Jun 5;21(2):259-261. doi: 10.5114/aic.2025.151854. eCollection 2025 Jun.
2
Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review.氯吡格雷预处理对ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗初始通畅率及预后的影响：一项系统评价
Circulation. 2008 Oct 28;118(18):1828-36. doi: 10.1161/CIRCULATIONAHA.107.749531. Epub 2008 Oct 13.
3
Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.接受经皮冠状动脉介入治疗并植入支架患者的氯吡格雷无反应性：一项系统评价和荟萃分析。
Am Heart J. 2007 Aug;154(2):221-31. doi: 10.1016/j.ahj.2007.04.014.
4
Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.非维生素 K 拮抗剂口服抗凝剂双联抗栓治疗在经皮冠状动脉介入治疗的心房颤动患者中的安全性和疗效：系统评价和荟萃分析。
J Am Heart Assoc. 2020 Aug 18;9(16):e017212. doi: 10.1161/JAHA.120.017212. Epub 2020 Aug 1.
5
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.氯吡格雷和强效 P2Y12 抑制剂对急性冠脉综合征或经皮冠状动脉介入治疗患者的死亡率和卒中的影响：系统评价和荟萃分析。
Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29.
6
Clinical Outcomes of Antithrombotic Strategies for Patients with Atrial Fibrillation After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后房颤患者抗栓策略的临床结局
Int Heart J. 2019 May 30;60(3):546-553. doi: 10.1536/ihj.18-464. Epub 2019 May 17.
7
Contemporary Use and Clinical Significance of Initial Triple Versus Double Therapy After Percutaneous Coronary Intervention for Myocardial Infarction in Patients With Atrial Fibrillation.经皮冠状动脉介入治疗心肌梗死后房颤患者初始三联疗法与双联疗法的当代应用及临床意义
J Am Heart Assoc. 2025 Jun 3;14(11):e038589. doi: 10.1161/JAHA.124.038589. Epub 2025 May 22.
8
Potent P2Y12 Inhibitors vs Clopidogrel in Cancer Patients Undergoing Percutaneous Coronary Intervention.强效P2Y12抑制剂与氯吡格雷在接受经皮冠状动脉介入治疗的癌症患者中的比较
Can J Cardiol. 2025 Jul;41(7):1241-1250. doi: 10.1016/j.cjca.2025.02.035. Epub 2025 Mar 8.
9
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.普拉格雷（Efient®）联合经皮冠状动脉介入治疗急性冠状动脉综合征（TA182综述）：系统评价与经济学分析
Health Technol Assess. 2015 Apr;19(29):1-130. doi: 10.3310/hta19290.
10
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.氯吡格雷预处理与经皮冠状动脉介入治疗患者的死亡率、心血管事件和主要出血的关系：系统评价和荟萃分析。
JAMA. 2012 Dec 19;308(23):2507-16. doi: 10.1001/jama.2012.50788.

本文引用的文献

1
Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis.载脂蛋白 2C19 失活多态性携带者冠心病患者氯吡格雷治疗后发生卒中的风险：基于种族的更新荟萃分析。
Eur J Intern Med. 2021 Aug;90:49-65. doi: 10.1016/j.ejim.2021.05.022. Epub 2021 Jun 4.
2
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动诊断和管理指南：欧洲心脏病学会（ESC）心房颤动诊断和管理特别工作组，由ESC欧洲心律协会（EHRA）特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
3
Effects of different CYP2C19 genotypes on prognosis of patients complicated with atrial fibrillation taking clopidogrel after PCI.不同CYP2C19基因型对PCI术后服用氯吡格雷的房颤合并患者预后的影响。
Exp Ther Med. 2018 Oct;16(4):3492-3496. doi: 10.3892/etm.2018.6650. Epub 2018 Aug 22.
4
Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients.在中国接受氯吡格雷治疗的患者中，CYP2C19和ABCB1基因多态性与氯吡格雷抵抗之间的关联。
Anatol J Cardiol. 2018 Feb;19(2):123-129. doi: 10.14744/AnatolJCardiol.2017.8097. Epub 2018 Jan 19.
5
The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients.CYP2C19基因多态性及非遗传因素对东亚冠心病患者氯吡格雷血小板抑制作用的影响
Thromb Res. 2017 Oct;158:22-24. doi: 10.1016/j.thromres.2017.07.032. Epub 2017 Aug 1.
6
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.CYP2C19*2和CYP2C19*17基因多态性在经皮冠状动脉介入治疗后氯吡格雷反应性中起关键作用：一项药物基因组学研究。
Basic Clin Pharmacol Toxicol. 2017 Jul;121(1):29-36. doi: 10.1111/bcpt.12763. Epub 2017 Mar 14.
7
Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity.冠状动脉疾病合并代谢综合征患者的氯吡格雷抵抗反应：高血糖和肥胖的作用
J Geriatr Cardiol. 2015 Jul;12(4):378-82. doi: 10.11909/j.issn.1671-5411.2015.04.009.
8
Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF).2010 年 ESC 心房颤动指南发布后七个欧洲国家的心房颤动管理：预防血栓栓塞事件-心房颤动欧洲登记研究（PREFER in AF）的初步结果。
Europace. 2014 Jan;16(1):6-14. doi: 10.1093/europace/eut263. Epub 2013 Oct 1.
9
Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.氯吡格雷治疗的中国患者中治疗时血小板高反应性的遗传决定因素。
Thromb Res. 2013 Jul;132(1):81-7. doi: 10.1016/j.thromres.2013.05.006. Epub 2013 May 29.
10
Mutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting.拟行冠状动脉旁路移植术患者的氯吡格雷抵抗和血小板功能的突变分析。
Genomics. 2013 Jun;101(6):313-7. doi: 10.1016/j.ygeno.2013.01.005. Epub 2013 Feb 24.

Prevalence of clopidogrel resistance in patients with atrial fibrillation undergoing percutaneous coronary intervention.

作者信息

Błaziak Mikołaj, Rakotoarison Oscar, Balcer Bartosz, Dolata Natalia, Wietrzyk Weronika, Kuliczkowski Wiktor

机构信息

Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.

Jan Mikulicz Radecki University Hospital, Wroclaw, Poland.

出版信息

Postepy Kardiol Interwencyjnej. 2025 Jun 5;21(2):259-261. doi: 10.5114/aic.2025.151854. eCollection 2025 Jun.

DOI:10.5114/aic.2025.151854
PMID:40656182
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12244363/
Abstract
摘要